The record-breaking year for biotech IPOs continues: Parabilis Medicines has raised $670M, topping Moderna's 2018 debut, to become the largest biotech listing on Nasdaq. $PBLS bizjournals.com/boston/news/…

今週 IPO した「zolucatetide / FOG-001」を軸にした Wnt / β-catenin 創薬企業 PBLS 流石に IPO 価格は高いよな。ポイントは、1つの薬をデスモイド腫瘍、FAP、ACP、HCC、MSS-CRCなど複数適応に展開する。

Saint Martin, Saint Barthelemy, Îles (dites) du Nord (Guadeloupe à ~200 km) ou FWI (French West Indies) de nos Caraïbes sont très proches: on se voit depuis la route. Saint Barth est aussi une des nombreuses tanières des millionnaires .. St Martin a des pbls de sécurité/drogue.

JUST IN: Parabilis Medicines ($PBLS) has priced a record-shattering $670M Nasdaq IPO, cementing a massive macro turnaround for the biopharma sector after the historic funding winter of 2025. This marks the second record-breaking biotech listing in less than 90 days, following the $625M April debut of obesity-focused Kailera Therapeutics ($KLRA). The multi-year capital drought—which saw public market entries blueprint a record low of just 15 listings last year—is officially over. The Cross-Market Alpha: This surge in institutional demand highlights a structural shift where public markets are aggressively pricing late-stage clinical assets with robust human data. Look closer at the pipeline drivers: $KLRA’s entire suite of oral and injectable GLP-1/GIP agonists was in-licensed directly from China’s Jiangsu Hengrui Pharmaceuticals. Western public markets are placing massive, multi-billion-dollar premium valuations on advanced Chinese innovations. With $PBLS locking down $670M to target the undruggable proteome via stabilized peptides, the liquidity window for elite cross-border assets is wide open. Expect a widespread valuation re-rating across late-stage global clinical pipelines. $PBLS $KLRA $XBI $IBB

JUST IN: Parabilis Medicines ($PBLS) priced a $670M Nasdaq IPO — now the largest biotech IPO on record. Worth pausing on what that signals after 2025's funding winter. It's the second record biotech listing in under 90 days, after Kailera Therapeutics' ($KLRA ) $625M debut in April. For context: US biopharma listings bottomed out around 15 last year. Two records back-to-back is a real shift in tone. What I'm actually watching is the China angle. Kailera's entire GLP-1/GIP suite — oral and injectable — was in-licensed from Jiangsu Hengrui. Public markets just put a multi-billion-dollar valuation on a pipeline sourced from Chinese R&D. That's the pattern worth tracking, not the headline number. Parabilis is a different bet — $670M to go after the "undruggable" proteome with stabilized peptides, plus a concurrent Regeneron placement. But the read-through is the same: the window for late-stage assets with real human data is open again, and cross-border deals are getting repriced. Watching whether this holds or fades. $PBLS $KLRA $XBI $IBB

US IPO Weekly Recap: SpaceX completes record-breaking $75 billion IPO and trades up 19% $SPCX $EROC $PBLS $FRBT $WHK $IPO #IPO zpr.io/3DCn58ax96D6

dont need this bloated scam $spcx make more shorting the garbage $spce $asts $eroc $pbls

late alert $pbls another good ipo short got some yest

$PBLS $KLRA $AVLN $ODTX $COAG $SPTX $XBI ‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing - Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week fiercebiotech.com/biotech/af…

📢 Biotech Stock News 6/12 @ Open $ELVN 13% Pricing of Upsized Public Offering $RCKT 6% Closing of Rare Disease Voucher Sale $KYMR 5% Ph1 Data for KT-621 $KLRS 5% Present at Clinical Trials Summit $ASND 4% Ph2 Data for TransCon® PTH $HCM 3% Sovleplenib Ph3 Data Highlighted $COGT 2% Bezuclastinib & JAK2 V617F Inhib. Data $IRON 2% Clinical Updates @ EHA'26 $BCRX 2% New clinical data for HAE portfolio $HRMY 1% Advances Registration-Ready CNS Asset $ABBV 0% New data for VENCLEXTA/VENCLYXTO $PBLS 0% Closing of Upsized Initial Public Offering $JAZZ -2% Update on Zepzelca Ph3 Trial $MBX -9% One-Year Data for Canvuparatide $LIXT -13% Acquired Battery Storage Comp. See the image and comments for more details!

$SPCX day IPO Monitor (Initial Public Offering) As of June 12, 2026 📅 Today 12/06/2026 | $SPCX | SPACE EXPLORATION TECHNOLOGIES CORP | Technology 🕐 Last 5 days 10/06/2026 | $SHOTU | RMG ML Sports Holdings | Sports 10/06/2026 | $EROC | ERock, Inc. | Energy 10/06/2026 | $JABRU | JAB Acquisition Corp I | Finance 10/06/2026 | $PBLS | Parabilis Medicines, Inc. | Healthcare 09/06/2026 | $ISNRU | Snow Rothschild Acquisition Corp. | Finance 09/06/2026 | $ELOX | Eloxx Pharmaceuticals, Inc. | Healthcare 09/06/2026 | $WHK | WhiteHawk Minerals Corp. | Mining 09/06/2026 | $OCACU | Ocean Capital Acquisition Corp | Finance 🔜 Next 5 days No IPOs scheduled for the next 5 days.

On today’s #BiotechHangout, @soowannaway (Graig Suvannavejh), @EricSchmidt151, @MatteisPaul & @FT’s @mroliverbarnes will cover the markets: Parabilis’ ($PBLS) record $670M IPO, Kardigan ($KARD) expected to price, SonoThera $125M Series B, City $100M Series B, Ethyreal $101M Series A, big secondary raises, $SMMT’s $500M follow-on pulled, deals: $INCY/Vega ($2B), $GSK/$NUVL ($10.6B), Roche/$NRIX ($3B), $JNJ/Firefly ($1B), $LLY/AlzeCure, $NVS/Orionis, data: $TNGX/$RVMD in 2L pancreatic cancer & readthroughs to $IDYA, $SNY CIDP miss hits $DNTH stock, $TAK’s oral TYK2 beats $BMY in Ph3 head-to-head, Sensorion drops hearing loss gene therapy, #EHA2026, $NGNE dosing safety update, plus Blood Cancer United buys remaining supply of Luvelta, & much more: twitter.com/i/spaces/1qJDzzD…

Welcoming Parabilis Medicines [PBLS] to the @Nasdaq Closing Bell in celebration of their listing. x.com/i/broadcasts/1jGXggYvb…

Cancer biotech Parabilis Medicines sets terms for $450 million IPO $PBLS $IPO #IPO zpr.io/Ye47Xm5jNqJr

This would be in addition to Howard. I think there’s a case for Morse to be pedestrianized from the lake to Clark. At their very least the stretch needs protected bike lanes. PBLs were ironically rejected by CDOT because people park in the painted bike lanes. 🫩

D’où l’idée de la GWOT au tournant du 21e s. comme processus d’intégration globale inédit, entériné par toutes les puissances (puis peu à peu quasi tous les États), en échange d’un cadrage et d’une boîte à outils puissants applicables par chacun à ses pbls politiques spécifiques.

Warm congrats to our Catalio portfolio company Parabilis Medicines that went public trading under the ticker $PBLS on @Nasdaq. Thrilled to be growing our partnership with @mmammen & team. This record-setting $670M IPO makes it the largest listing in the sector’s history!

Parabilis Medicines is built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Proud to welcome $PBLS! #NasdaqListed